VERTEX PHARMACEUTICALS INC / MA: management transactions · United States · SEC (Form 4)

About VERTEX PHARMACEUTICALS INC / MA

Vertex Pharmaceuticals Incorporated is a U.S.-based biopharmaceutical company listed on the NASDAQ (ticker: VRTX), in the United States. Founded in 1989 and headquartered in Boston, Massachusetts, with its global headquarters in Boston and an international hub in London, Vertex has become one of the leading developers of therapies for serious diseases, most notably cystic fibrosis (CF). The company combines a highly profitable commercial base with a long-duration R&D strategy aimed at broadening revenue beyond CF over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/ex-991_q22025.htm?utm_source=openai)) Vertex built its franchise on a series of first-in-class and best-in-class CF medicines designed to address the underlying biology of the disease. Its marketed portfolio includes TRIKAFTA/KAFTRIO, the company’s largest revenue driver, along with KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI. More recently, Vertex has expanded its commercial base with ALYFTREK, CASGEVY, and JOURNAVX, signaling an important transition toward a more diversified business model. In 2025, management emphasized that TRIKAFTA/KAFTRIO continued to anchor performance, while ALYFTREK, CASGEVY, and JOURNAVX started to contribute meaningful incremental sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000875320/000087532026000056/vrtx-20251231.htm?utm_source=openai)) From a competitive standpoint, Vertex enjoys an unusually strong moat within CF. It has deep scientific expertise, a dominant commercial position in the disease area, and substantial regulatory and development barriers that are difficult for competitors to replicate. That said, the investment case is increasingly about diversification: the company is no longer just a CF story, but its CF franchise remains the core earnings engine. Investors are also watching Vertex’s pipeline in acute pain and genetic diseases, which could expand its addressable market and reduce product concentration risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm?utm_source=openai)) Geographically, Vertex has a broad operational footprint across the U.S., Europe, and selected other markets. Its offices and functions extend beyond the United States into Germany, Brazil, India, and Ireland, supporting commercialization, clinical development, manufacturing, and regulatory activities. This international structure is important for both product launches and the company’s global clinical footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1806837/000110465926019165/verx-20251231x10k.htm?utm_source=openai)) Recent milestones reinforce the company’s growth trajectory. Vertex reported 2025 total revenue of $12.0 billion, up 9% year over year, and guided 2026 revenue to $12.95 billion to $13.1 billion, with management expecting non-CF products to contribute $500 million or more. The company also continued rolling out ALYFTREK and JOURNAVX while expanding CASGEVY, underscoring a strategic shift from a single-disease powerhouse toward a multi-franchise biotechnology platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm?utm_source=openai))